BIOGNOSYS
14.9.2021 08:02:06 CEST | Business Wire | Press release
Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, announced today that they have entered a collaboration with Evotec , a life science company that discovers, develops, and provides highly effective therapeutics for patients, to advance the adoption of next-generation proteomics in drug discovery and clinical research.
Evotec has been a long-term user of Biognosys’ software and kits within its research. The two companies are now working closely together to integrate Biognosys’ next-generation proteomics data analysis platform in drug discovery and clinical proteomics.
Under the extended partnership, Evotec will continue to utilize Spectronaut, Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics , in its research. The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types.
Additionally, Evotec is implementing Biognosys’ unique workflow for mass spectrometry facility management. This workflow combines Biognosys’ proprietary QuiC software with its patented indexed Retention Time (iRT) technology and iRT Kit to generate near real-time readouts from mass spectrometry instrument raw files for quality control.
The collaboration uniquely combines Evotec’s partnered drug discovery and development business model and focus on data-driven precision medicine, and Biognosys’ expertise and know-how in applying next-generation proteomics to transforming drug discovery and development.
Kristina Beeler, PhD, CBO of Biognosys, comments: “We are excited to deploy the power of proteomics to address some of the key challenges of drug development and work closely with Evotec to de-risk therapeutic assets early on.”
Christoph Schaab, PhD, SVP Head of Proteomics & Metabolomics at Evotec, comments: “Discovery proteomics is increasing its importance to derive functional insights in the early stages of the drug development pipeline. We are thrilled to integrate Biognosys’ proteomics data analysis expertise into Evotec’s pre-clinical and clinical development solutions for the benefit of our biopharma partners.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the worldleading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005750/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Expands Combo Antenna Portfolio with Rugged Multi-network Solutions for Demanding IoT Deployments25.6.2026 10:00:00 CEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, has expanded its external antenna portfolio with four new combo antennas designed to simplify deployment of connected devices across smart cities, fleet management, industrial automation, utilities, public safety and transport applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625825719/en/ Quectel expands combo antenna portfolio with rugged multi-network solutions for demanding IoT deployments The new YEMA206J1AM, YEMA301J1AM, YEMN308L1BM and YENA00L5AH antennas combine cellular, Wi-Fi and GNSS technologies in rugged, compact form factors that help engineers accelerate product development while ensuring reliable connectivity in demanding outdoor and industrial environments. Featuring IP67-rated enclosures, high inter-antenna isolation, flexible mounting options and support for multiple wireless standards, the antennas provide a versatile so
Safe Software Appoints Nabil Lodey as Its First EMEA Senior Executive to Drive Regional Expansion25.6.2026 10:00:00 CEST | Press release
Nabil Lodey joins as VP EMEA to lead Safe Software's expansion across the region, bringing deep geospatial industry expertise and an established network across the partner and customer ecosystem. Safe Software (Safe), creator of FME, the only All-Data, Any-AI enterprise integration platform, today announced the appointment of Nabil Lodey as VP EMEA, where he will drive growth in the company's presence and customer base across the region. His appointment builds directly on Safe's operational expansion into the UK and Ireland, announced in June 2025. Nabil joins Safe from 1Spatial, a long-standing Safe partner and FME reseller, where he served as Managing Director for the UK and Ireland. He brings a deep, first-hand understanding of Safe's business and of the FME Platform, having worked closely with the technology and its customer base. That familiarity positions him to further accelerate Safe's regional expansion plan while deepening the company's commitment to support clients and partn
Floward Scales Customer Service to Handle 13x Peak Demand With Infobip AgentOS25.6.2026 10:00:00 CEST | Press release
AI-powered customer service enables seamless experiences during peak seasons Global AI-first cloud communications platform Infobip has partnered with Floward, the leading online flower and gifting company in the Middle East and the UK, to transform customer service using AI agents on Infobip’s AgentOS platform. By moving beyond traditional rule-based chatbots to agentic AI, Floward now handles up to 13x higher peak-day conversation volumes while maintaining fast response times and high customer satisfaction. As a same-day delivery business built around major occasions such as Mother’s Day, Valentine’s Day, and Ramadan, Floward experiences intense seasonal demand spikes. Working with Infobip’s AI consultants, Floward redesigned its customer journeys on Infobip AgentOS, deploying a multi-agent system that intelligently routes conversations to specialized AI agents for tasks such as address collection, FAQs, and order changes, with seamless escalation to live agents when needed. A key inn
ISC 2026: KAYTUS Unveils Gigawatt-Scale AI Infrastructure and Intelligent Management to Empower Europe’s AI Future25.6.2026 09:02:00 CEST | Press release
End-to-end, fully factory-prefabricated modular AI Factory deployment in just a few months, with full-stack intelligent management from GPU to rack, to the entire data center. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, unveiled two core solutions at ISC 2026, designed for next-generation AI data centers: a gigawatt-scale, fully prefabricated containerized liquid-cooled data center solution and KSManage Ultra, an intelligent operations management platform for AI Factories. Together, the solutions target the escalating efficiency, performance, scalability, and reliability requirements of AI-era infrastructure, enabling faster deployment, optimized thermal management, and unified operations across large-scale AI computing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625809392/en/ KAYTUS prefabricated containerized liquid cooled data center solution The KAYTUS gigawatt-scale
LR Health & Beauty SE Successfully Completes Financial Realignment – Strong Foundation for Growth and Long-Term Partnerships25.6.2026 09:00:00 CEST | Press release
Successful completion of the financial realignment enables full focus on growth and further strengthening operational excellence Planned investments in production and logistics will enhance efficiency, flexibility, and delivery capabilities Further international growth, including expansion into new markets, targeted LR Health & Beauty SE, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, has successfully completed its financial realignment, establishing the foundation for the company’s stable and forward-looking development. With the achievement of the final milestone, an intensive and demanding process has been successfully concluded. LR has fundamentally realigned its financing structure and significantly strengthened its capital base. An initial financing tranche of EUR 10 million was provided at the end of March, followed by a second tranche of the same amount in June. Jörg Körfer, CEO of LR Health & Beauty SE, comments: “The pas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom